Sign In
Buy SAN
$14.10
-0.0100 (-0.0709%)
At Close: Jul 31, 2026
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
05:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Sanofi lance son premier Accélérateur digital porté par de nouveaux talents et centré sur la croissance
09:21am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
Sanofi lance son premier Accélérateur digital porté par de nouveaux talents et centré sur la croissance
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
09:21am, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
08:45pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Communiqué de presse: La FDA approuve Dupixent® (dupilumab) – premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 mois à 5 ans
08:45pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
La FDA approuve Dupixent® (dupilumab) – premier médicament biologique pour le traitement de la dermatite atopique modérée à sévère de l’enfant âgé de 6 mois à 5 ans
Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariés
05:30am, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariés
Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
05:30am, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
Sanofi launches 2022 global Employee Stock Purchase Plan for 86.000 people
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2022
05:48pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marc
Sanofi: Information concerning the total number of voting rights and shares – April 2022
05:48pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement
Is Banco Santander (SAN) Stock Undervalued Right Now?
01:40pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Is Banco Santander (SAN) Stock Undervalued Right Now?
11:18am, Thursday, 02'nd Jun 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
05:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Communiqué de presse: La FDA accorde la désignation de « Traitement innovant » à l’efanesoctocog alpha pour le traitement de l’hémophilie A
05:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
La FDA accorde la désignation de « Traitement innovant » à l’efanesoctocog alpha pour le traitement de l’hémophilie A
Zacks Industry Outlook Highlights UBS Group AG, Banco Santander S.A., and Bancolombia S.A
01:06pm, Tuesday, 31'st May 2022 Zacks Investment Research
UBS Group AG, Banco Santander S.A., and Bancolombia S.A are part of Zacks Industry Outlook article.
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
05:00am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
